Nav: Home

Disfiguring eye symptoms diminish in Graves' eye disease drug trial

May 03, 2017

ANN ARBOR, Mich. - The disease is characterized by inflammation and a buildup of tissue around the eyes that cause them to bulge painfully from their sockets.

There has never been a safe and effective treatment for Graves' eye disease, also known as thyroid eye disease, for the one million Americans with the condition. Patients see inconsistent benefit from anti-inflammatory medicines and complex orbital surgery helps give some a more natural appearance once the disease has run its course.

The results of a clinical trial led by the University of Michigan Kellogg Eye Center offers hope for those with moderate-to-severe active TED. Patients had a significant reduction in eye symptoms after treatment with teprotumumab, a study drug the U.S. Food and Administration called a "breakthrough therapy."

Most study patients in the trial who got the active drug instead of a placebo had reduced eye bulging, eye pain and swelling and improved quality of life, the study's primary and secondary end points.

For some, the therapeutic benefit was rapid, occurring within six weeks of intravenous infusions of the drug that blocks what researchers say is an autoimmune attack on muscles around the eyes.

Published in the New England Journal of Medicine, the clinical trial data represents 25 years of research led by the lead study author the Kellogg Eye Center's Terry J. Smith, M.D., an endocrinologist and Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences.

TED is a rare condition associated with Graves' disease, an autoimmune disorder that causes an overproduction of thyroid hormone, or hyperthyroidism. Symptoms include swelling of the eyelids, constant stare, bulging eyes, eyelid retraction, optic neuropathy, double vision and other symptoms.

Approximately 25 to 50 percent of those with Graves' disease will develop TED, most of them women.

Previous findings in Smith's laboratory suggested that an insulin-like growth factor 1 receptor (IGF-1R) plays an important role in Graves' disease and other autoimmune diseases.

"Specifically, we have found that there is an unusually high presence of IGF-1 receptors on cells surrounding the eye in TED," says Smith, who is widely recognized for his groundbreaking research on treatments for TED and related autoimmune disorders.

Building on this discovery, an outgrowth of basic science research conducted at the University of California, Los Angeles, and then at the Kellogg Eye Center, Smith and study author Raymond Douglas, M.D., Ph.D., a Graves' eye disease specialist and renowned oculoplastics surgeon, initiated the study of thyroid-associated ophthalmopathy.

"The eyes are particularly susceptible to Graves' disease because the autoimmune attack often targets the eye muscles and connective tissue surrounding the eye," Douglas says. "This occurs as a consequence of these tissues containing proteins that are shared with the thyroid gland."

The study, lasting 24 weeks and involving 88 patients, was the largest multi-center Graves' eye disease trial. Patients were recruited between July 2, 2013 and Sept. 23, 2015, from 15 sites across the United States as well as Italy and Germany and the United Kingdom.

Study investigators examined the benefit of teprotumumab, a monoclonal antibody shown to inhibit IGF-1 function and was originally developed as a cancer drug.

Although teprotumumab failed to exhibit efficacy in patients with cancer, the team believed it might be useful in interrupting the TED disease process.

At the end of the trial, 69 percent of study patients receiving infusions of teprotumumab once every three weeks had reduced eye bulging (proptosis) and increased quality of life compared to 20 percent in the placebo group.

Patients were randomly assigned to receive either a placebo or an active drug. Neither participants nor researchers knew which medicine was being used so they could describe what happened in the trial without bias.

Some participants had results after two injections at week six when, according to the study, a reported 43 percent of patients in the treatment group compared to 4 percent in the placebo group had a response.

Patients who responded to the treatment reached the study's primary end point of a reduction by 2 points or more in the severity of the disease, which was measured on a 7-point Clinical Activity Score, and reduction by 2 mm or more in the degree of proptosis. Secondary end points included better quality of life.

Those in the treatment group had a baseline Clinical Activity Score of 5.1. The marked reduction in proptosis is similar to the kind of results surgical patients would expect, authors note.

"The findings have implications for other autoimmune diseases in which IGF-1 reception has already been implicated such as rheumatoid arthritis," Smith says.

The most common side effect of treatment was nausea. Muscle spasms and diarrhea were also reported, particularly among patients with gastrointestinal disease. The only drug-related adverse event was hyperglycemia in patients with diabetes; these events were controlled by adjusting medication for diabetes.

The results provide inroads for a new therapy to safely minimize the severity of the eye condition.

"The study is one of two pivotal clinical trials needed to achieve registration of teprotumumab as the first approved therapy to prevent TED symptoms," says David Madden, president and chief executive officer of River Vision Corporation, which has entered an agreement to manufacture the drug with CMC Biologics in Copenhagen, Denmark.

The drug cannot be prescribed currently for TED patients. A follow-up clinical trial is underway, but not recruiting participants, and is expected to be complete in 2018.
-end-
River Vision sponsored the study and collaborated with academic researchers on the study design. Researchers received grants from the National Institutes of Health, Research to Prevent Blindness, the FDA's Office of Orphan Products Development, and others.

Michigan Medicine - University of Michigan

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at Radiolab.org/donate.